Acromegaly
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Biochemically confirmed diagnosis of acromegaly by an increased IGF-1 level (e.i. mean > 2 standard deviations (SD) for age and sex) and an insufficient suppression of serum GH levels (e.i. GH *1 mU/l) during an oral glucose tolerance test (OGTT).
Exclusion criteria
Exclusion criteria: Excluded from participation in this study will be subjects who are/have: * Mentally incompetent; * Pregnant or breastfeeding; * Inadequately supplied, unstable or untreated hormonal deficiencies; * Known inflammatory or infectious diseases or an immunosuppressive status; * Using hormonal therapy: hormonal contraceptives (42) or hormonal substitution therapy (only applicable for the subgroups of patients); * Using medication interfering with adiponectines, such as thiazolidinediones; * Severe comorbidities: active malignancy (except for basal cell carcinoma), serious psychiatric pathology; * A systolic blood pressure *160 mmHg and/or a diastolic blood pressure *100 mmHg; * Known untreated or unstable diabetes mellitus or ischemic cardiovascular disease; * A self-reported alcohol consumption of >21 units per week.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: circulating inflammatory markers, metabolic parameters and CV parameters, effects of GH, IGF-1 and oxLDL on immune cells in vitro | — |
Secondary
| Measure | Time frame |
|---|---|
| Vascular ultrasound measurements (IMT, PWV and FMD). Muscle morphometry and inflammatory and metabolic profile. Whole genome analysis. Gut and mouth microbiome. Epigenetic profiles. Urine-analysis. | — |
Countries
Netherlands
Outcome results
None listed